Leading Product Sales

Nov 10. 2021

(¥ million)

Brand name Active Ingredient Indications Launch Date Sales 2019 Sales 2020 Apr.-Sep.
Sales 2021 Annual
(estimated)
Vidaza azacitidine myelodysplastic syndrome/
acute myeloid leukemia
Mar-2011/
Mar-2021
15,652 15,350 9,059 17,200
Uptravi selexipag pulmonary arterial hypertension/
chronic thromboembolic pulmonary hypertension
Nov-2016/
Aug-2021
6,182 6,804 3,851 8,600
Tramal, Onetram tramadol hydrochloride cancer pain, chronic pain Sep-2010 7,153 6,906 3,444 6,100
Viltepso viltolarsen Duchenne muscular
dystrophy
Japan May-2020
U.S. Aug-2020
- 2,387 3,142 8,800
Gazyva obinutuzumab CD20-positive follicular lymphoma Aug-2018 4,527 5,312 2,616 6,100
Adcirca tadalafil pulmonary arterial hypertension Dec-2009 5,405 5,474 2,599 4,800
Zalutia tadalafil urinary disorder caused by benign prostatic hyperplasia Apr-2014 13,328 6,743 2,191 3,200
Cialis tadalafil erectile dysfunction Jul-2009 4,472 2,677 1,212 2,500
Defitelio defibrotide sodium sinusoidal obstruction syndrome Sep-2019 1,071 1,970 956 2,100
Erizas dexamethasone cipecilate allergic rhinitis Dec-2009 2,387 2,444 649 2,500
Profit in co-promotion   5,963 8,442 4,464 9,000
Revenues from the licensing of industrial property rights   15,860 24,338 20,964 32,000
Pharmaceuticals   101,643 106,478 63,430 119,300
Functional Food   14,994 15,406 8,138 15,700
Net Sales   116,637 121,885 71,568 135,000